ARCA biopharma CEO Michael R. Bristow to Be Interviewed Live Today on Clear Channel Business Talk Radio

ARCA biopharma CEO Michael R. Bristow to Be Interviewed Live Today on Clear 
Channel Business Talk Radio 
Interview Scheduled at 11:05am PDT / 12:05 pm MDT / 2:05pm EDT on the
Traders Network Radio Show, Hosted by Michael Yorba 
WESTMINSTER, CO -- (Marketwired) -- 03/19/14 --  ARCA biopharma, Inc.
(NASDAQ: ABIO), a biopharmaceutical company developing
genetically-targeted therapies for cardiovascular diseases, today
announced that Michael R. Bristow, president and CEO, will be
interviewed live today by host Michael Yorba on Clear Channel
Business Talk Radio's The Traders Network Show. Any interested
parties may tune in and listen live via Clear Channel's nationally
syndicated iHeart Radio stream. 
The live interview details are as follows: 
Date: Wednesday, March 19, 2014
 Start Time: 11:05am PDT | 12:05pm
MDT | 2:05pm EDT (U.S.)
 Network: Clear Channel
 Station: DFW 1190AM
 Show: The Traders Network
 Host: Michael Yorba
 Live iHeart
Radio Stream:  
About ARCA biopharma
 ARCA biopharma is dedicated to developing
genetically-targeted therapies for cardiovascular diseases. The
Company's lead product candidate, Gencaro(TM) (bucindolol
hydrochloride), is an investigational, pharmacologically unique
beta-blocker and mild vasodilator being developed for atrial
fibrillation. ARCA has identified common genetic variations that it
believes predict individual patient response to Gencaro, giving it
the potential to be the first genetically-targeted atrial
fibrillation prevention treatment. ARCA has a collaboration with
Medtronic, Inc. for support of the GENETIC-AF trial. For more
information please visit 
About Clear Channel: Clear Channel's Media and Entertainment division
has the largest reach of any radio or television outlet in America
with 243 million monthly listeners. It serves 150 cities through 850
owned radio stations in the U.S., as well as more than 140 stations
in New Zealand and Australia. 
About Michael Yorba: Mr. Yorba is the founder of Yorba Media and
featured host on Clear Channel. For the past six years he has
produced and hosted The Traders Network Show broadcasted live daily
on Clear Channel DFW 1190AM KFXR from 1pm - 3pm CT, Monday-Friday. 
Michael Yorba interviews the front-page Titans about the latest in
capital markets, CEO milestones, trading tools, real estate
acquisitions and market trends. Learn how the experts use risk
management techniques to build fully diversified portfolios and what
it takes to put up big board earnings. It's a fast moving,
high-energy show that presents stocks, commodities, bonds, forex,
derivatives, real estate, political trends, technology trends, crowd
funding and impact investment insights in a new light and keeps
audience asking for more... shift your thinking and join us as we
deliver "tomorrow's ideas today" on Clear Channel's The Traders
Network Show. 
A PR Event 
Safe Harbor Statement 
This press release and the anticipated interview contain
"forward-looking statements" for purposes of the safe harbor provided
by the Private Securities Litigation Reform Act of 1995. These
statements include, but are not limited to, statements regarding,
potential timing for patient enrollment in the GENETIC-AF trial, the
sufficiency of the Company's capital to support its operations, the
potential for genetic variations to predict individual patient
response to Gencaro, Gencaro's potential to treat atrial
fibrillation, future treatment options for patients with atrial
fibrillation, the role of AF burden in diagnosis and treatment of
atrial fibrillation and the potential for Gencaro to be the first
genetically-targeted atrial fibrillation prevention treatment. Such
statements are based on management's current expectations and involve
risks and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements as
a result of many factors, including, without limitation, the risks
and uncertainties associated with: the Company's financial resources
and whether they will be sufficient to meet the Company's business
objectives and operational requirements; results of earlier clinical
trials may not be confirmed in future trials, the protection and
market exclusivity provided by the Company's intellectual property;
risks related to the drug discovery and the regulatory approval
process; and, the impact of competitive products and technological
changes. These and other factors are identified and described in more
detail in ARCA's filings with the SEC, including without limitation
the Company's annual report on Form 10-K for the year ended December
31, 2012, and subsequent filings. The Company disclaims any intent or
obligation to update these forward-looking statements. 
Image Available: 
Image Available: 
Investor & Media Contact:
Derek Cole 
+1 (720) 940-2163  
Press/Media Contact:
Matthew Bird
MUNCmedia Public Relations
+1 (917) 409-8211 
Press spacebar to pause and continue. Press esc to stop.